LIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer
Given as first treatment, selpercatinib more than doubled the time to progression compared with platinum-pemetrexed chemotherapy plus pembrolizumab in RET fusion-positive lung cancer, and protected against brain metastases.
Overview
Phase 3 trial of 261 patients with untreated advanced RET fusion-positive non-squamous non-small-cell lung cancer randomised to selpercatinib or platinum-pemetrexed with or without pembrolizumab.
Median progression-free survival was 24.8 versus 11.2 months (hazard ratio 0.46) in the intention-to-exclude-pembrolizumab population, response 84 versus 65 percent, and the cumulative incidence of central nervous system progression was lower with selpercatinib.
- Median progression-free survival 24.8 vs 11.2 months; hazard ratio 0.46.
- Objective response 84 percent vs 65 percent.
Selpercatinib is the established first-line treatment for RET fusion-positive lung cancer, and the trial adds to evidence that targeted therapy should precede chemo-immunotherapy in driver-positive disease.
- Open-label; overall survival immature.
- Crossover to selpercatinib at progression was permitted.
Similar pages
not linked directly; found by shared links- Key paperLIBRETTO-001: selpercatinib in RET fusion-positive non-small-cell lung cancer
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer, New England Journal of Medicine.
- TrialA Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.
- TrialA Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.
- Key paperLIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer
- Key paperKEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares LIBRETTO-431, Selpercatinib, Pembrolizumab.
- TrialLIBRETTO-531
Shares LIBRETTO-431, Selpercatinib.
- Key paperKEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer